Delcath Systems, Inc.
Moat Score — Delcath Systems, Inc.
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | FDA approval of HEPZATO KIT for a narrow orphan indication, combined with CE-marked CHEMOSAT device status and proprietary percutaneous hepatic perfusion technology, gives Delcath regulatory and technical protection that is difficult for new entrants to replicate quickly. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small, single-product commercial-stage company, Delcath has no manufacturing or distribution scale advantage over larger interventional oncology device and pharmaceutical competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Securing a dedicated CMS J-Code, transitional drug pass-through status, and NTAP designation supports premium reimbursement for a therapy with no direct FDA-approved liver-directed competitor in its specific orphan indication. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in Delcath's business; the product's value to one hospital or patient does not increase as more hospitals adopt it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a hospital has trained interventional radiologists and credentialed its team to perform the percutaneous hepatic perfusion procedure, there is real inertia against switching to an alternative locoregional therapy, though this cuts both ways as a barrier to Delcath's own site expansion. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The approved indication (hepatic metastases from uveal melanoma) is a rare disease with a small patient population, which limits the commercial incentive for competitors to develop a rival liver-directed product for the same narrow market. |